Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women

American Journal of Medicine

Volumn 103, Issue 4, 1997, Pages 291-297

  Stock, John L ^a,j   Bell, Norman H ^b   Chesnut III, Charles H ^c   Ensrud, Kristine E ^d   Genant, Harry K ^e   Harris, Steven T ^e   McClung, Michael R ^f   Singer, Frederick R ^g   Yood, Robert A ^h   Pryor Tillotson, Suzanne ⁱ   Wei, L ⁱ   Santora II, Arthur C ⁱ  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d VA MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^g SAINT JOHN'S HEALTH CENTER   (United States)

^h SAINT VINCENT HOSPITAL   (United States)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

^j Memorial Health Care   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM CARBONATE; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; OSTEOCALCIN; PLACEBO;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

NON-PROGRAMMATIC;

ADULT; AGED; ALENDRONATE; BONE DENSITY; BONE REMODELING; FEMALE; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PELVIC BONES; TIME FACTORS;

EID: 0030700023     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)00130-7     Document Type: Article

References (22)

1. Lombardi A, Santora AC. Clinical trials with bisphosphonates. Bone Miner. 1993;22 (Suppl):59-70.
2. Ott SM. Clinical effects of bisphosphonates in involutional osteoporosis. J Bone Miner Res. 1993;8(Suppl 2):S597-S606.
3. Fleisch H. New bisphosphonates in osteoporosis. Osteoporosis Int. 1993; 2(Suppl):15-22.
4. Balena R, Toolan BC, Shea M, Markatos A, et al. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest. 1993;92:2577-2586.
5. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995;333:1437-1443.
6. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1997;348:1535-1541.
7. Chesnut CH III, McClung MR, Ensrud KE, et al. Alendronate treatment of the post-menopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med. 1995;99:144-152.
8. Reginster JY, Lecart MP, Deroisy R, et al. Prevention of postmenopausal bone loss by tiludronate. Lancet. 1989;ii:1469-1471.
9. Rossini M, Gatti D, Zamberlan N, et al. Long-term effects of a treatment course with oral alendronate of post-menopausal osteoporosis. J Bone Miner Res. 1994;9:1833-1837.
10. Landman JO, Hamdy NAT, Pauwels EKJ, Papapoulos SE. Skeletal metabolism in patients with osteoporosis after discontinuation of long term treatment with oral pamidronate. J Clin Endocrinol Metab. 1995;80:3465-3468.
11. Vasikaran SD, Khan S, McCloskey EV, Kanis JA. Sustained response to intravenous alendronate in postmenopausal osteoporosis. Bone. 1995;17:517-520.
12. Delmas PD, Schlemmer A, Gineyts E, et al. Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Miner Res. 1991;6:639-644.
13. Passeri M, Baroni MC, Pedrazzoni M, et al. Intermittent treatment with intravenous 4-amino-l-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis. Bone Miner. 1991;15:237-247.
14. Harris ST, Gertz BJ, Genant HK, et al. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab. 1993;76:1399-1406.
15. Christiansen C, Christiansen MS, Transbol I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet. 1981;i:459-461.
16. Overgaard K, Hansen MA, Nielsen V-AH, et al. Discontinuous calcitonin treatment of established osteoporosis - effects of withdrawal of treatment. Am J Med. 1990;89:1-6.
17. Garnero P, Shih WJ, Gineyts E, et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 1994;79:1693-1700.
18. Sato M, Grasser W, Endo N, et al. Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastucture. J Clin Invest. 1991;88:2095-2105.
19. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest. 1996;97:2692-2696.
20. Compston JE. The therapeutic use of bisphosphonates. BMJ. 1994; 309:711-715.
21. Greenspan SL, Holland S, Maitland-Ramsey L, et al. Nocturnal stimulation of parathyroid hormone: a mechanism to explain the continued improvement in bone mineral density following alendronate therapy. J Bone Miner Res. 1995;10(Suppl I):S449. Abstract.
22. Kanis JA, Gertz BJ, Singer F, Ortolani S. Rationale for the use of alendronate in osteoporosis. Osteoporosis Int. 1995;5:1-13.